CAPR · As filed with the SEC
Capricor Therapeutics balance sheet, by quarter
The statement as Capricor Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONDENSED CONSOLIDATED BALANCE SHEETS · USD
| USD | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 |
|---|---|---|---|---|
| ASSETS | ||||
| CURRENT ASSETS | ||||
| Cash and cash equivalents | 20,935,187 | 105,421,484 | 287,847,312 | 19,510,383 |
| Marketable securities | — | — | — | 79,055,588 |
| Marketable securities | 216,999,595 | 173,188,430 | 30,281,603 | — |
| Receivables | — | 0 | 59,167 | 59,167 |
| Prepaid expenses and other current assets | 4,193,195 | 4,478,895 | 4,751,674 | 2,326,543 |
| TOTAL CURRENT ASSETS | 242,127,977 | 283,088,809 | 322,939,756 | 100,951,681 |
| PROPERTY AND EQUIPMENT, net | 36,346,335 | 28,502,617 | 18,312,238 | 11,068,078 |
| OTHER ASSETS | ||||
| Lease right-of-use assets, net | 88,615,221 | 13,158,500 | 13,537,820 | 13,929,710 |
| Other assets | 1,646,302 | 1,533,591 | 1,159,480 | 488,738 |
| TOTAL ASSETS | 368,735,835 | 326,283,517 | 355,949,294 | 126,438,207 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||
| CURRENT LIABILITIES | ||||
| Accounts payable | 3,079,714 | 3,927,941 | 1,654,754 | 2,719,416 |
| Accrued expenses | 16,391,869 | 10,528,351 | 15,557,646 | 9,932,488 |
| Lease liabilities, current | 1,489,838 | 841,135 | 202,376 | 120,094 |
| CIRM liability, current | 0 | 6,339,862 | 6,421,984 | 3,376,259 |
| Deferred revenue, current | 12,000,000 | 12,000,000 | 12,000,000 | 12,000,000 |
| TOTAL CURRENT LIABILITIES | 32,961,421 | 33,637,289 | 35,836,760 | 28,148,257 |
| LONG-TERM LIABILITIES | ||||
| CIRM liability, net of current | — | — | 0 | 0 |
| Lease liabilities, net of current | 89,555,524 | 13,943,595 | 14,320,389 | 14,422,695 |
| TOTAL LONG-TERM LIABILITIES | 89,555,524 | 13,943,595 | 14,320,389 | 14,422,695 |
| TOTAL LIABILITIES | 122,516,945 | 47,580,884 | 50,157,149 | 42,570,952 |
| STOCKHOLDERS' EQUITY | ||||
| Common stock, $0.001 par value, 100,000,000 shares authorized, 58,108,989 and 57,370,909 shares issued and outstanding, respectively | 58,109 | 57,665 | 57,371 | 45,717 |
| Additional paid-in capital | 625,877,806 | 617,718,525 | 610,330,105 | 357,684,987 |
| Accumulated other comprehensive income | (163,541) | (253,727) | 283,154 | 844,122 |
| Accumulated deficit | (379,553,484) | (338,819,830) | (304,878,485) | (274,707,571) |
| TOTAL STOCKHOLDERS' EQUITY | 246,218,890 | 278,702,633 | 305,792,145 | 83,867,255 |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | 368,735,835 | 326,283,517 | 355,949,294 | 126,438,207 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.